This directory serves as a resource listing of active biotech that develop therapeutics, diagnostics and/or medtech. The companies listed in this directory are not representative of the companies that are active members of the Biotech and Money community.
Add / Amend your company listing for free
(only active biotech ie. therapeutic, diagnostic and medtech companies are eligible for listing)
Austria
Activartis develops a proprietary dendritic cell-based cancer immune therapy, AV0113. AV0113 is manufactured from a patient?s tumour tissue und white blood cells. It is individually tailored for each patient?s tumour and is, therefore, in principle applicable for any type of neoplastic disease. In a randomised clinical trial for the treatment of brain cancer, significantly improved one-year survival is found as an early trend for efficacy. Based on these results, Activartis seeks a partnership with an international pharmaceutical company for late stage clinical development and worldwide market introduction of AV0113 for the treatment of brain cancer, and for clinical development in other indications.
Biotech company dedicated to the discovery and development of novel therapeutics for the treatment of conditions with unmet medical need, focused on chronic pain. Based on world class research, Akron has developed a "drug repurposing" strategy.
The lead drug candidate, AKR 202, is scheduled to enter a phase IIa proof-of-concept study in pain associated with osteoarthritis, having already obtained a regulatory ?thumbs up? from a BfArM scientific advice meeting, with first-patient-in in Q4?13. Top-line data is expected Q4'14.
AKR 202 can be administered once daily orally, and has a favourable short and long-term clinical safety profile also when compared to current pain therapies. AKR 202 showed analgesic efficacy across a range of different rodent models of pain, coupled with anti-inflammatory and potentially disease-modifying effects. AKR 202 represents a novel mechanism of action for the treatment of pain, with a potential for first-in-class status.
The lead drug candidate, AKR 202, is scheduled to enter a phase IIa proof-of-concept study in pain associated with osteoarthritis, having already obtained a regulatory ?thumbs up? from a BfArM scientific advice meeting, with first-patient-in in Q4?13. Top-line data is expected Q4'14.
AKR 202 can be administered once daily orally, and has a favourable short and long-term clinical safety profile also when compared to current pain therapies. AKR 202 showed analgesic efficacy across a range of different rodent models of pain, coupled with anti-inflammatory and potentially disease-modifying effects. AKR 202 represents a novel mechanism of action for the treatment of pain, with a potential for first-in-class status.
Apeiron, based in Vienna, Austria, is a biotech company with a focus on biological and immunological approaches to treat cancer and related conditions. Apeiron's lead project is a monoclonal antibody for the treatment of neuroblastoma that will be submitted for market authorization next year. Three additional projects are in clinical phase II and two more in preclinical testing.
APEPTICO is a privately-held biotechnology company based in Austria, developing peptide-based products targeting chronic and life-threatening diseases, including oedematous respiratory failure, acute lung injury, primary graft dysfunction and high altitude pulmonary oedema. APEPTICO's AP301-peptide is subject to two Phase II clinical studies. By concentrating on synthetically produced protein structures APEPTICO avoids general risks associated with gene- and cell-technologies. APEPTICO makes use of its technology platforms PEPBASE(TM) and PEPSCREEN(TM) to significantly reduce cost and to shorten time to market.
Arsanis is committed to the development of fully human monoclonal antibodies against severe infectious diseases for which current prophylactic or therapeutic approaches are ineffective or non-existent.
Avienne Pharmaceuticals GmbH is a private, Austrian, biotechnology company committed to developing innovative, proprietary, small molecule drugs with anti-angiogenic activity to treat dermatological and ophthalmological diseases of clear unmet need. Avienne initially focuses on developing the first effective topically applied therapy designed to alter blood vessels of the skin to reduce erythema and teleangiectasias of rosacea. The company is also exploring the potential of the pronounced antiangiogenic activity of its lead compound in AMD.
Biomay is engaged in the research, discovery and development of allergy immunotherapeutics. The company's products are designed to not only alleviate allergy symptoms, but offer long term cure.
BIRD-C GmbH & Co KEG specializes in the development of effective and safe next generation vaccines and drug delivery systems based on its proprietary Bacterial Ghost (BG) platform technology.
CELLMED is an Austrian based biotechnology company and develops PROCURE
FIBREX Medical Inc., a bio-pharmaceutical company, develops therapeutics for acute and intensive care in cardiovascular and inflammatory conditions. It offers FX06 that prevents reperfusion injury after myocardial infarction.
Greiner Bio-One's subsidiary Lambda is a biotech company that develops and produces molecular diagnostic solutions for the detection of pathogens (viruses and bacteria) from various specimens.
Further fields of research and development include food diagnostics and quality control products for the pharmaceutical industry.
Their novel GENSPEED
Further fields of research and development include food diagnostics and quality control products for the pharmaceutical industry.
Their novel GENSPEED